Diagnostic method for Biomarkers of Adverse Coronary Events

Title:

Diagnostic method for biomarkers of adverse coronary events

Category:

Diagnostic

NCS:

Inventors: David A. Ford

Summary:

The present invention provides diagnostic methods for characterizing an individual's risk for
developing or having an adverse coronary event. More particular, the present invention is
generally directed to characterizing an individual's risk for developing or having an adverse
coronary event by determining the presence of myeloperoxidase-derived chlorinated lipids in
body fluids and tissues. The invention is predicated upon the discovery that tissue plasmalogens
are targeted by hypochlorous acid produced by activated neutrophil-derived myeloperoxidase
(MPO). This reaction leads to the production of a family of chlorinated lipids useful in the
diagnostic method of the present invention and that function as a better prognostic indicator
of future adverse coronary events than either MPO or C-reactive protein (CRP). Chlorinated
lipids are a catalytic product of MPO activity (i.e., one molecule of MPO can produce hundreds
to thousands of molecules of chlorinated lipids) making their dynamic range in plasma much
greater than that of MPO. Further, in comparison to CRP, chlorinated lipids are a much more
specific marker of inflammation. The present invention also provides kits that include assays
for determining the presence or levels of myeloperoxidase-derived chlorinated lipids in body
tissues of fluids.

Patent:

U.S. 8,137,978

Manager:

Stephanie Kimzey, MBA

Office of Technology Management
Fusz Hall, Suite 253
Phone: 314-977-7731
kimzeysl@slu.edu